News

FDA Seeking Comments on Olaparib by June 11

The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval. Olaparib is an oral poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA repair pathway deficiencies to preferentially kill cancer cells.  AstraZeneca, the company that manufactures the... 

Breastfeeding, Birth Control Pills May Reduce Ovarian Cancer Risk Among Women with BRCA Gene Mutations

(May 16, 2014) Breastfeeding, tubal ligation – also known as having one’s “tubes tied” – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis from a team at the University of Pennsylvania’s... 

OCRF Research Shows How Ovarian Tumors Elude Immune System

Greg Motz, PhD (May 6, 2014) Tumors use numerous mechanisms to escape detection and killing by the immune system. Results from OCRF-funded research, reported May 4, 2014 in the prestigious journal Nature Medicine, show that ovarian cancer cells (and others) establish a protective barrier that prevents... 

Imaging Predicts Response in Ovarian Cancer

(April 30, 2014) A positive pretreatment imaging test more than doubled the likelihood of disease control in platinum-resistant advanced ovarian cancer treated with the folate receptor-targeted drug vintafolide (trade name Vynfinit), results of a small phase II study showed. The research was reported in... 

Liz Tilberis: A Tribute

Liz Tilberis bridged the worlds of high-fashion and everyday home-life seamlessly. Her effortless ability to transition between the two serves as a reminder that women touched by ovarian cancer play many roles, and live in many different worlds, but ultimately, all share the same goal – to find... 

News from AACR: Irregular Menses Linked to High Risk of Ovarian Cancer

(April 15, 2014) Prolonged (>35 days), infrequent, or anovulatory menstrual cycles was associated with as much as a two-fold increase in ovarian cancer and more than a three-fold increase in the risk of fatal ovarian cancer, according to a 50-year, prospective follow-up in 14,403 women. The findings... 

Physical Activity Associated with Lower Risk of Ovarian Cancer Mortality

(April 8, 2014) A team of researchers have found that vigorous physical activity prior to ovarian cancer diagnosis was associated with a lower risk of ovarian cancer mortality.  The findings were published in Gynecologic Oncology. There is limited knowledge of the association of modifiable lifestyle... 

OCRF Research Identifies Fusion Gene Common in Ovarian Cancer

(April 7, 2014) A group of OCRF-funded researchers at Baylor College of Medicine have found a “fusion gene” that is present in 20% of high grade serous ovarian cancer patients.  The finding, which was published in PLOS Genetics, was supported in part by OCRF grants to Martin Matzuk, MD,... 

2015 OCRF Requests for Proposals Now Available

(April 1, 2014)  Ovarian Cancer Research Fund is now accepting Letters of Intent for its three research grant programs.  Letters of Intent must be submitted by May 6, 2014 at 5:00pm ET. Click here for complete application information.  MORE

Gene Mutation Causes Rare Ovarian Cancer

(March 25, 2014) In what is being hailed as a major discovery, findings published this week indicate that researchers have discovered a gene mutation that causes Small Cell Carcinoma of the Ovary, Hypercalcemic type. OCRF Scientific Advisory Committee member, and former grantee, Douglas A. Levine, MD,...